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ABSTRACT  
A survey of the literature reveals that the number of coumarin derivatives having heterocyclic moieties either as substituent groups or fused 
with parent coumarin nucleus possesses a variety of functions and are widely used in drugs and dyes. Because of this wide utility, the synthesis 
of coumarin has remained a subject of active interest. Looking at the importance of these heterocoumarins and with a view to exploring new 
methods of their synthesis, the present work was undertaken and  this synthesis deals with  various 2-aryl-pyrido [3,2-c] coumarins. The 
compounds have been synthesized by reacting Mannich bases of various 4-hydroxy coumarins with pyridinium salts of various aroyl methyl 
bromides in the presence of ammonium acetate and acetic acid. All the compounds synthesized have been characterized by analytical and 
spectral data. 
Keywords: Pyrido, Coumarins, Krohanke’s reaction. 
 
Article Info: Received 04 Jan 2020;     Review Completed 16 Feb 2020;     Accepted 26 Feb 2020;     Available online 15 March 2020 
Cite this article as:  
Pandya MK, Parekh TH, Chhasatia MR, Vala ND, Synthesis and characterization of some novel coumarin based various 2-
aryl-pyrido [3,2-c] coumarins, Journal of Drug Delivery and Therapeutics. 2020; 10(2):158-163  
http://dx.doi.org/10.22270/jddt.v10i2.3933   
*Address for Correspondence:   
Nileshkumar D. Vala, Department of Chemistry Sardar Patel University, Vallabh Vidyanagar, Gujarat, (INDIA) 
 
 
INTRODUCTION:  
The work incorporated in this series of synthesis of various 
2-aryl-pyrido [3,2-c] coumarins. The compounds have been 
synthesized by reacting appropriate Mannich bases of 4-
hydroxy coumarins with various aroyl methyl pyridinium 
bromide salts in the presence of ammonium acetate and 
acetic acid utilizing Krohnke’s mechanism. The structures of 
all the 2-aryl-pyrido [3, 2-c] coumarins synthesized have 
been supported by analytical and spectral data. 
A literature survey reveals that a very large number of 
coumarin derivatives containing heterocyclic moieties are 
used in drugs and dyes. The varied biological activities of the 
coumarins fused with other heterocycles have encouraged 
researchers with regard to the procedures and substrates, 
improving the feasibility of broad families of these 
compounds. Several biological activities have been claimed 
for compounds comprising both coumarins and coumarins 
fused to a pyridine ring. For instance, the coumarin nucleus 
is present in promising drug candidates as nonpeptidic HIV 
protease inhibitors [1] such as topoisomerase II [2] and 
tyrosine kinase [3] inhibitors. Coumarins joined to pyridines 
have been reported to possess antiallergic [4], anticoagulant 
[5], antidiabetic [6] activities, and even analgesic [7] properties, 
being characterized by phenanthrene like structure as found 
in tetrahydrocannabinol. The pyrido [2,3-c]coumarin 
skeleton constitutes the backbone of Santiagonamine [8]. 
This alkaloid has been isolated from Berberis Darvinii 
(Berberidaceae) and has shown interesting wound healing 
properties [9-15]. 
Thus pyrido fused coumarins become an important class of 
heterocyclic fused coumarin derivatives and therefore brief 
literature account on various synthetic methods available for 
pyrido fused coumarins are presented in research work
 
 
 
Pandya et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2020; 10(2):158-163 
ISSN: 2250-1177                                                                               [159]                                                                                       CODEN (USA): JDDTAO 
Experimental  
2.1 Preparation of 4-hydroxy coumarin, 6-methyl-4-hydroxy  coumarin and 8-methyl-4-hydroxy coumarin (1a-c). 
O O
OH
R2
R1
OH
R2
R1
COOH
COOH
ZnCl 2
POCl 3
+
 
In a 500 ml round bottom flask attached with a reflux 
condenser and gas absorption trap, a mixture of appropriate 
phenol (0.2 mole), malonic acid (22g, 0.2 mole), anhydrous 
zinc chloride (80g, 0.6 mole) and phosphorous oxychloride 
(60 ml, 0.4 mole) was heated with stirring at 60-65 oC for 35 
hours. The yellow coloured mixture was cooled and 
decomposed with water and left overnight. The resulting 
crude 4-hydroxy coumarin was filtered out, washed with 
water and dried. This crude product was purified by 
dissolving it in 10% sodium bicarbonate solution, filtering 
and reprecipitating by adding dilute HCl solution. The 4-
hydroxy coumarin was separated out as a yellowish-white 
solid. This was filtered out, washed with water, dried and 
recrystallized from ethanol-water. 
2.2  Preparation of 6-chloro-4-hydroxy coumarin (1d). 
In a 250 ml round bottom flask fitted with reflux condenser, 
a mixture of p-chloro phenol (25.6g, 0.2 mole), malonic 
acid(10.4g, 0.1mole) and phosphorous oxychloride POCl3 
(30.4 ml) was placed. The reaction mixture was heated for 30 
minutes on boiling water bath. It was cooled and poured into 
ice cold water. The white solid obtained was filtered and 
washed with cold water. It was then washed with saturated 
sodium bicarbonate solution to remove unreacted malonic 
acid. Finally it was washed with water and dried. Thus 
diester [CH2(CO2Ph-pCl)2] obtained was recrystallized from 
ether-hexane. Yield 22g, 68%, m.p. 1150C. 
The above diester (20g) and anhydrous aluminum chloride 
(20.6g) were taken in a round bottom flask. The flask was 
stoppered and shaken vigorously for 2-3 minutes. A reflux 
condenser provided with gas absorption tube was attached 
and the flask was heated in an oil bath at 180-185  for 30 
minutes. The reaction mixture was allowed to cool to room 
temperature and then flask was immersed in an ice bath. The 
reaction mixture was decomposed by dilute HCl (1:7) over a 
period of about 2 hours. The content was then heated on 
steam bath for 30 minutes with vigorous stirring in order to 
effect the complete decomposition. The solid product 
obtained was filtered out and washed with water and dried. 
The product was then dissolved in 5% aqueous sodium 
hydroxide solution and the solution was filtered. The product 
was then reprecipitated by adding dilute HCl, until solution 
was acidic. The precipitates were filtered out, washed with 
water and dried. It was recrystallized from ethyl acetate-
hexane.
 
 
2.3 Preparation of Mannich bases of 4-hydroxy coumarins(1a-d). 
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a;  R = H,      R 1= H 
b;  R = CH 3,  R 1= H
d;  R = Cl,      R 1= H
c;  R = H,          R 1= CH 3
1(a-d)
Ethanol
+HCHO
  
In a 100 ml round bottom flask equipped with magnetic 
stirrer, formaldehyde (37% formalin solution) (0.025mole) 
and ethyl amine (0.03mole) were taken with ethanol (25ml) 
and stirred for 30 minutes. Thenafter an appropriate 4-
hydroxy coumarin (0.025mole) dissolved in ethanol (15ml) 
was added dropwise to above well stirred solution during 30 
minutes at room temperature. The reaction mixture was 
further stirred at room temperature for overnight. The solid 
obtained was filtered out and washed with ether and dried. 
The products were enough pure and were directly used for 
further reaction. 
 
 
2.4 (i) Preparation of phenacyl bromide. 
A solution of acetophenone (40g, 0.33 mole) in anhydrous 
ether (60 ml) was placed in a three necked flask equipped 
with a dropping funnel and a gas absorption tube. The flask 
was placed in an ice bath and was allowed to cool to 0-50C. A 
trace amount of anhydrous AlCl3 (0.1g) was introduced and 
bromine (52.8g, 0.33 mole) was added drop wise with 
stirring during 30 minutes. The reaction mixture was 
allowed to come to room temperature and was stirred 
further for 1 hour. Then pet.ether (40-600C) (100 ml) was 
added. The phenacyl bromide was separated out as white 
solid. It was filtered out and was washed with a mixture of 
pet. ether (40-60 0C) and water (100 ml, 1:1). It was dried 
and recrystallized from rectified spirit. 
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2.4 (ii) Preparation of substituted phenacyl bromides. 
An appropriate acetophenone (0.5 mole) in acetic acid (100 
ml) was taken in a three necked flask equipped with a 
dropping funnel and a condensor with gas absorption tube. 
Bromine (0.5 mole) was added gradually from dropping 
funnel with stirring at room temperature during 30 minutes. 
The reaction mixture was stirred for 2 hours at room 
temperature. It was then poured into ice cold water (500 
ml). The substituted phenacyl bromide was separated out as 
white solid. It was filtered out and washed with water and 
dried. It was recrystallized from rectified spirit. The 
following phenacyl bromides were prepared. 
2.5  Preparation of aroyl methyl pyridium salts (2a-d).
 
CH2PyBr
O
R
Pyridine
    Toluene
( 2a-d  ) 
O
R
CH2Br
 
An appropriate phenacyl bromide (0.25 mole) was dissolved 
in dry toluene (100 ml) at room temperature. Dry pyridine 
(0.25 mole) was added slowly to the above solution. The 
reaction mixture was then heated at 100 OC for 30 minutes. 
It was then allowed to come to room temperature. Phenacyl 
bromide pyridinium salt was separated out as a white solid. 
It was filtered out and washed with dry toluene. It was dried 
at 60-70 OC for 4-5 hours. 
2.6 Synthesis of 2-aryl-pyrido [3, 2-c]coumarins (3a-p).  
In a 100 ml round bottom flask equipped with a magnetic 
stirrer, aroyl methyl bromide pyridinium salt (2) 
(0.006mole) in glacial acetic acid (20ml) was taken. To this 
ammonium acetate (0.06mole) was added with stirring at 
room temperature. Then a solution of appropriate Mannich 
base of 4-hydroxy coumarin (1) (0.006mole) in glacial acetic 
acid (20ml) was added with stirring at room temperature for 
15 minutes and the reaction mixture was further stirred for 
1 hour at room temperature.  Then after the reaction 
mixture was refluxed for 8 hours at 140 oC. It was then 
allowed to come to room temperature and was poured into 
ice-cold water. A sticky mass was separated out which was 
then extracted with chloroform (3x30ml). The chloroform 
layer was then washed with 5% NaHCO3 and then with 
water. It was then dried over anhydrous sodium sulphate. 
The chloroform was removed under reduced pressure. The 
gummy residue obtained was subjected to column 
chromatography using silica gel and ethyl acetate-
compounds thus obtained were recrystallized from 
chloroform-hexane.
 
O O
N
R2
R
R1
(3a-p)
 
RESULT AND DISCUSION 
The new method developed in our laboratory for the 
synthesis of 2-aryl-pyrido [3, 2-c]coumarins, 4-hydroxy 
coumarin were reacted with the Mannich base of 
acetophenone under Krohnke’s reaction condition. The 
tautomeric form of 4-hydroxy coumarin undergoes Michael 
addition with vinyl aroyl ketone, generated insitu from the 
Mannich base and gives the 1,5-dione intermediate which 
gets converted into the product in the presence of the 
NH4OAc/AcOH under Krohnke’s reaction condition. Now it is 
interesting that the compound can also be synthesized by 
interchanging the functionality of the reacting components. 
i.e if a Mannich base of the 4-hydroxy coumarin is reacted 
with the aroyl methyl pyridinium salt under Krohnke’s 
reaction condition, the product obtained will be the same. 
The Mannich base of the 4-hydroxy coumarin generates the 
intermediate, coumarin quinone methide which provides the 
α, β-unsaturated carbonyl system and Michael addition of 
aroyl methyl pyridinium salt converts it into a 1,5-dione 
intermediate which finally gives the product. The research 
work of is utilized and various 2-aryl-pyrido [3,2-c] 
coumarine has been synthesized. 
The condensation of  various Mannich bases (1a-d) with 
appropriate aroyl methyl pyridinium salts (2a-d), in the 
presence of ammonium acetate and acetic acid under 
Krohanke’s reaction condition, gave the 2-aryl-pyrido[3,2-
c]coumarins (3a-p).  
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+ _
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3(a-p)
c:   R2=OCH3
d:   R2=Cl
 b:  R2=CH3
c:   R=H,       R1=CH3,       
d:   R=Cl,       R1=H,   
 b:  R=CH3,   R1=H,       
a:   R=H,       R1=H,       a:  R2=H
 
a :  R  =  H,  R 1  =  H,   R 2  = H 
b :  R  =  H,   R 1 = H,    R 2  = CH 3  
c :  R  =  H,   R 1 = H,    R 2  = OCH 3  
d :  R  =  H,   R 1 = H,    R 2  = Cl  
e :  R  =  CH 3 ,   R 1 = H,    R 2  = H 
f :  R  =  CH 3 ,   R 1 = H,    R 2  = CH 3  
g :  R  =  CH 3 ,   R 1 = H,    R 2  = OCH 3  
h :  R  =  CH 3 ,   R 1 = H,    R 2  = Cl  
 i :  R  =  H,   R 1 = CH 3 ,   R 2  = H 
 j :  R  =  H,   R 1 = CH 3 ,   R 2  = CH 3  
k :  R  =  H,   R 1 = CH 3 ,   R 2  = OCH 3  
 l :  R  =  H,   R 1 = CH 3 ,  R 2  = Cl  
            m :  R  =  C l ,   R 1 = H,    R 2  = H 
n:  R  =  Cl ,   R 1 = H,    R 2  = CH 3  
o :  R  =  Cl ,   R 1 = H,    R 2  = OCH 3  
p :  R  =  Cl ,   R 1 = H,   R 2  = Cl  
 
Among the Mannich bases of 4-hydroxy coumarins 1(a-d) 
used, 1a was known and hence its formation was confirmed by 
comparison of its melting point with the literature melting 
point. The (1b, 1c, 1d), were new and their structures were 
supported by analytical and spectral data. 
Compound 1b 
IR: νmax 1720 cm-1(δ-lactone carbonyl stretching of 
coumarin), 1605cm-1 (aromatic C=C stretching), 3365cm-1(O-
H stretching), 3325cm-1(N-H stretching), 2960cm-1 (aliphatic 
C-H stretching), 3045cm-1 (aromatic C-H stretching). 
NMR: 0.9-1.5δ (3H, triplet,-CH2-CH3), 2.3δ (3H, singlet, Ar-
CH3), 2.6-3.6δ (2H quartet, -CH2-CH3), 4.0δ (2H, singlet,-CH2-
NH), 6.8-8.1δ (5H, multiplet,three aromatic protons +,       -NH 
and –OH protons merged).  
Compound 1c 
IR:  νmax 1710 cm-1(δ-lactone carbonyl stretching of 
coumarin), 1600cm-1( a r om a ti c  C=C str e tc hi ng) ,  
3360c m - 1 (O - H str e tc hi ng) ,  3340cm - 1 ( N- H 
str e tc hi ng),  2935c m - 1  ( a l i pha t ic  C- H str e tc hi ng),  
3055c m - 1 (a r om a ti c  C- H str e tc hi ng) .  
NMR: 0.9-1.6δ (3H, triplet, CH2-CH3), 2.4δ (3H, singlet, Ar-
CH3), 2.7-3.4δ (2H, quartet,        -CH2-CH3), 4.0δ (2H, singlet,-
CH2-NH), 6.8-8.0δ (5H, multiplet, three aromatic protons +           
-NH and –OH protons merged).                       
Compound 1d 
IR:  ν max 1715 cm-1(δ-lactone carbonyl stretching of 
coumarin), 1610cm-1(aromatic C=C stretching), 3370cm-1(O-
H stretching), 3315cm-1(N-H stretching), 2950c m -
1 ( a l i pha t ic  C- H str e tc hi ng) ,  3040c m - 1  ( ar oma tic 
C- H str e tc hi ng) .    
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NMR: 0.8-1.6δ (3H, triplet, -CH2-CH3), 2.5-3.7δ (2H, qurtet, -
CH2-CH3), 4.0δ (2H, singlet, -CH2-NH), 6.8-8.4δ (5H, multiplet, 
three aromatic protons + -NH and   –OH protons merged). 
All aroyl methyl pyridinium bromide salts (2a-d) were 
prepared by using literature method. 
The condensation of Mannich bases of 4-hydroxy coumarins 
(1a-d) with aroyl methyl pyridinium bromide salts (2a-d) 
under Krohnke’s reaction condition proceeded smoothly and 
gave the expected 2-aryl-pyrido[3,2,-c]coumarin (3a-p) in  
55-61 % yield. The structures of all compounds (3a-p) were 
confirmed by analytical and spectral data.               
Thus the reaction of Mannich base of 4-hydroxy coumarin 
(1b) with aroyl methyl pyridinium bromide salt (2c) gave the 
expected 2-aryl-pyrido [3,2,-c]coumarin (3g) as yellow solid 
product. 
The IR spectrum of compound (3g) showed a strong band at 
1715 cm-1 which is due to carbonyl stretching of lactone ring 
present in coumarin nucleus. The bands observed at 1610 
cm-1 and 1430cm-1 can be assigned to aromatic C=C and C=N 
stretching vibrations respectively. Compound showed bands 
at 1235cm-1 and 1040cm-1 which can be attributed to 
asymmetric and symmetric C-O-C stretching due to the 
methoxyl group present in the phenyl ring. Compound 
showed a medium band at 835cm-1 which can be assigned to 
C-H banding vibration for p-disubstituted phenyl ring 
present at C2. The compound showed bands at 2930cm-1 and 
3030cm-1 which can be assigned to aliphatic C-H stretching 
of methyl group attached at C9 and aromatic C-H stretching 
respectively. 
The PMR spectrum (60MHz) of compound (3g) showed a 
singlet 2.5δ is due to three protons of methyl group present 
at C9. A methoxyl signal appeared as a singlet at 3.9δ. A 
multiplet observed between 7.0-9.2δ (9H) is due to nine 
aromatic protons.       
The structure of (3g) was further supported by high 
resolution PMR (300MHz) and 13C spectral data. The PMR 
(300MHz) spectrum of compound (3g) showed a singlet at 
2.49δ (3H). This is due to methyl protons attached at C9. A 
methoxyl signal appeared at 3.90δ (3H) as a singlet. A 
multiplet observed between 7.04-8.54δ (9H) is due to nine 
aromatic protons.  
A signal appeared at 21.12δ is due to methyl carbon attached 
at C9. A signal appeared at 56.61δ is for carbon of –OCH3 
present in the compound. The signals appeared at 114.62, 
117.13, 118.43, 119.48, 124.80, 126.23, 129.95, 130.63, 
133.23, 134.66, 136.83, 138.02, 138.98, 151.29, and 151.95δ, 
corresponding to fifteen carbons is due to aromatic carbons. 
The most down field signal appeared at 162.34δ can be 
assigned to the carbonyl carbon of the δ-lactone ring of 
coumarin. In the absence of 13C DEPT spectra the assignment 
of primary, secondary and tertiary carbons was not possible. 
The IR and PMR (60MHz) spectral data for the other 
compounds (3a-p) are given below. 
Co mp ou nd  3 a 
IR: ν max 1725 cm-1(δ-lactone carbonyl stretching of 
coumarin), 1610cm-1 a nd 1440c m - 1  ( C=C a nd C=N 
str e tc hi ng),  3035c m - 1 (a r om ati c  C- H str etc hi ng) .  
NMR:  7 .2- 9 .0δ  ( 11H ,  m ulti ple t ,  ar oma tic 
pr otons) .  
Co mp ou nd  3 b 
IR: ν max 1720 cm-1(δ-lactone carbonyl stretching of 
coumarin), 1600cm-1 and 1435cm-1 (C=C and C=N 
stretching), 2950cm-1 (aliphatic stretching of methyl group), 
3045cm-1 (aromatic C-H stretching). 
NMR:  2.4δ (3H, singlet, -CH3), 7.1 -9.0δ (10H, multiplet, 
aromatic protons). 
Co mp ou nd  3 c 
IR:  ν m a x  1725 c m - 1 ( δ - la c tone  ca r bonyl 
str e tc hi ng  of  c ouma ri n) ,  1610cm - 1  a nd 1440c m -
1 ( C=C a nd C=N  str e tc hi ng),  1245c m - 1  ( C- O - C 
str e tc hi ng) ,  3035c m - 1 (a r om ati c  C- H str etc hi ng) .  
NMR:  3.8δ ( 3H ,  s i ng le t , -OCH 3 ) , 7 .0-
8 .8δ( 10H ,m ult i ple t ,a r om ati c  pr otons) .  
Co mp ou nd  3 d 
IR:  ν m a x  1710 c m - 1 ( δ - la c tone  ca r bonyl 
str e tc hi ng  of  c ouma ri n) ,  1615cm - 1  a nd 1445c m -
1 ( C=C a nd C=N str e tchi ng) ,  3045cm - 1 ( ar oma tic 
C- H str e tc hi ng) .  
NMR:  7.1- 9 .0δ  ( 10H ,  m ult i ple t ,  ar oma tic 
pr otons) .  
Co mp ou nd  3 e  
IR:  ν m a x  1700 c m - 1 ( δ - la c tone  ca r bonyl 
str e tc hi ng  of  c ouma ri n) ,  1605cm - 1  a nd 1430c m -
1 ( C=C a nd C=N str e tc hi ng),  2945cm - 1 ( a l i pha t ic 
C- H str e tc hi ng  of  m e thyl  gr oup),  3040c m -
1 ( a r om ati c  C- H str etc hi ng) .  
NMR:  2.4δ( 3H , s i ng le t , - CH 3 ) , 7 .1- 9 .0δ  ( 10H ,  
m ult i ple t ,  a r oma ti c  pr otons) .  
Co mp ou nd  3 f  
IR:  ν m a x 1710c m - 1 ( δ - lac tone  c ar bonyl  str e tc hi ng 
of  c ouma ri n) ,  1605cm - 1  a nd 1435cm - 1 ( C=C a nd 
C=N str e tc hi ng),  2935cm - 1 ( a l i pha t ic  C - H 
str e tc hi ng  of  m ethyl  gr oup) ,  3030cm - 1 ( ar oma tic 
C- H str e tc hi ng) .  
NMR: 2.4δ( 6H , s i ng le t, two–CH 3 ) , 7 .0-
9 .2δ( 9H ,m ult i ple t ,a r om a ti c  pr otons) .  
Co mp ou nd  3 g 
IR:  ν m a x 1715 c m - 1 ( δ - la c tone  c ar bonyl  str e tc hi ng 
of  c ouma ri n) ,  1610c m - 1a nd 1430cm - 1 ( C=C a nd 
C=N str e tc hi ng) ,  1235cm - 1  ( C- O - C str e tc hi ng) ,  
2930c m - 1 (a l i pha t i c  C- H str e tc hi ng  of  m e thyl 
gr oup) ,  3030c m - 1 (a r om a ti c C- H stre tc hi ng) .  
NMR: 2.5δ( 3H , s i ng le t, - CH 3 ) , 3 .9δ(3H , s i ng le t , -
OCH 3 ) , 7 . 0- 9 .2δ(9H,  m ult i ple t ,  a r om a ti c  pr otons) .  
Co mp ou nd  3 h 
IR:  ν m a x 1715 c m - 1 ( δ - la c tone  c ar bonyl  str e tc hi ng 
of  c ouma ri n) ,  1615c m - 1a nd 1445cm - 1 ( C=C a nd 
C=N str e tc hi ng),  2935cm - 1 ( a l i pha t ic  C - H 
str e tc hi ng  of  m ethyl  gr oup) ,  3035cm - 1 ( ar oma tic 
C- H str e tc hi ng) .  
NMR:  2.5δ  ( 3H ,  s i ng le t ,  - CH 3 ) ,  7 .0- 9 .2δ  ( 9H ,  
m ult i ple t ,  a r oma ti c  pr otons) .  
Co mp ou nd  3 i 
IR:  ν m a x 1725 c m - 1 ( δ - la c tone  c ar bonyl  str e tc hi ng 
of  c ouma ri n) ,  1605c m - 1a nd 1440cm - 1 ( C=C a nd 
C=N str e tc hi ng),  2940cm - 1 ( a l i pha t ic  C - H 
str e tc hi ng  of  m ethyl  gr oup) ,  3035cm - 1 ( ar oma tic 
C- H str e tc hi ng) .  
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NMR: 2.4δ( 3H ,  s i ng le t , - CH 3) , 7 .1-9 .0δ  ( 10H ,  
m ult i ple t ,  a r oma ti c  pr otons) .  
Co mp ou nd  3 j  
IR:  ν m a x 1710 c m - 1 ( δ - la c tone  ca r bonyl  stre tc hi ng 
of  c ouma r i n) ,  1605cm - 1  a nd 1430c m - 1 ( C=C a nd 
C=N str e tc hi ng) ,  2950c m - 1  ( a l i pha ti c  C- H 
str e tc hi ng  of  m ethyl  gr oup) ,  3050cm - 1 ( ar oma tic 
C- H str e tc hi ng) .  
NMR: 2.5δ( 6H , s i ng le t, two- CH 3 ) , 7.0- 9 .2δ  ( 9H ,  
m ult i ple t ,  a r oma ti c  pr otons) .  
Co mp ou nd  3 k 
IR:  ν m a x 1710 c m - 1 ( δ - la c tone  c ar bonyl  str e tc hi ng 
of  c ouma r i n) ,  1610cm - 1  a nd 1430c m - 1 ( C=C a nd 
C=N str e tc hi ng),  1250cm - 1 ( C- O- C str e tc hi ng) ,  
2940c m - 1 (a l i pha t i c  C- H str e tc hi ng  of  m e thyl 
gr oup) ,  3030c m - 1 (a r om a ti c  C- H str e tc hi ng) .  
NMR: 2.5δ( 3H , s i ng le t, - CH 3 ) , 3 .9δ(3H,si ngle t, -
OCH 3 ) , 6 .9- 8 .8δ(9H,  m ult i ple t ,   a r oma tic 
pr otons) .  
Co mp ou nd  3 l  
IR:  ν m a x 1725c m - 1 ( δ - lac tone  c ar bonyl  str e tc hi ng 
of  c ouma ri n) ,  1600c m - 1a nd 1435cm - 1 ( C=C a nd 
C=N str e tc hi ng),  2950cm - 1 ( a l i pha t ic  C- H 
str e tc hi ng  of  m ethyl  gr oup) ,  3030cm - 1 ( ar oma tic 
C- H str e tc hi ng) .  
NMR:  2.5δ  ( 3H ,  s i ng le t ,  - CH 3 ) ,  7 .2- 9 .2δ  ( 9H ,  
m ult i ple t ,  a r oma ti c  pr otons) .  
Co mp ou nd  3 m 
IR:  ν m a x  1720 c m - 1 ( δ - la c tone  ca r bonyl 
str e tc hi ng  of  c oum a ri n) ,  1615c m - 1   
a nd 1435cm - 1 ( C=C a nd C=N str e tc hi ng) , 3035c m -
1 ( a r om ati c  C- H str etc hi ng) .  
NMR: 7.2- 9 .0δ  (10H ,  m ult i ple t ,  ar oma tic 
pr otons) .  
Co mp ou nd  3 n 
IR:  ν m a x 1710c m - 1 ( δ - lac tone  c ar bonyl  str e tc hi ng 
of  c ouma ri n) ,  1610c m - 1a nd 1445cm - 1 ( C=C a nd 
C=N str e tc hi ng),  2935cm - 1 ( a l i pha t ic  C- H 
str e tc hi ng  of  m ethyl  gr oup) ,  3055cm - 1 ( ar oma tic 
C- H str e tc hi ng) .  
NMR:  2.5δ  ( 3H ,  s i ng le t ,  - CH 3 ) ,  7 .0- 9 .0δ  ( 9H ,  
m ult i ple t ,  a r oma ti c  pr otons) .  
Co mp ou nd  3 o 
IR:  ν m a x 1710c m - 1 ( δ - lac tone  c ar bonyl  str e tc hi ng 
of  c ouma r i n) ,  1610cm - 1   
a nd 1430c m - 1 ( C=C a nd C=N str e tc hi ng) ,  1245c m -
1  ( C- O - C stre tc hi ng),  3050cm - 1 ( ar oma tic  C- H 
str e tc hi ng).  
NMR: 3.8δ( 3H ,  s i ng let ,  - OCH 3) ,  6 .8- 8 .9δ  ( 9H ,  
m ult i ple t ,  a r oma ti c  pr otons) .  
Co mp ou nd  3 p 
IR:  ν m a x 1715 c m - 1 ( δ - la c tone  c ar bonyl  str e tc hi ng 
of  c ouma r i n) ,  1615cm - 1   
a nd 1425cm - 1 ( C=C a nd C=Nstr e tc hi ng) , 3055c m -
1 ( a r om ati c  C- H str etc hi ng) .  
NMR:   7.0- 9 .2δ  ( 9H,  m ulti ple t ,  ar oma tic 
pr otons) .  
CONCLUSION  
This series deals with synthesis of various 2-aryl-pyrido [3,2-
c] coumarins. The compounds have been synthesized by 
reacting Mannich bases of various 4-hydroxy coumarins with 
pyridinium salts of various aroyl methyl bromides in the 
presence of ammonium acetate and acetic acid. 
REFERENCES 
1. Johannes and G. GerhardGer. Offen., 2,013,262 (1970); CA, 
76,87159z (1972). 
2. P. Manfred and V. Christos Ger. Offen., 2,553,294 (1977); CA, 87, 
103365 (1977). 
3. F. Bayer A.-G. Fr. Demande., 2,010,602 (1968); CA, 74, 4703g 
(1971). 
4. N. Otto, D. Alfons, C. W. Schellhammer and B. Otto Ger. 1,794,396 
(1974); CA, 82,32468f (1975). 
5. U. Hirotoshi, K. Teijiro and K. Kenzo Kogyo Kagaku Zasshi, 
 73(10),2200 (1970);  CA, 74,55115z (1971). 
6. S. Kazuaki Japan 7231,391 (1969); CA, 78, 73666s (1973). 
7. E. Sigeharu, S. Katsunobu and S. Goichi Ger. Offen., 2,005,933 
(1969); CA, 74,65585s (1971). 
8. S. S. El-morsy, A. A. Fadda and M. S. El-hossini J. Ind. Chem. Soc., 
LXV, 699 (1988). 
9. K. H. Sinnur and S. SiddappaInd. J. Chem., 25B, 894 (1986). 
10. D. I. Brahmbhatt and U. R. Pandya Ind. J. Chem., 40B, 419-21-
(2001). 
11. D. I. Brahmbhatt and B. R. Hirani Ind. J. Chem., 33B, 1072-(1994). 
12. D. I. Brahmbhatt , G. B. Raolji, S. U. Pandya and U. R. Pandya 
Ind.J.Chem., 38B,212-15 (1999). 
13. D. I. Brahmbhatt and U. R. Pandya Ind. J. Chem., 42B, 145-49 
 (2003). 
14. R. Crossley, D. E. Beattie, Adrain C.W.Curran, D. G. Hill, and A. E. 
Lawrence Journal of Medicinal Chemistry, Vol (20), 718-721, 
(1977). 
15. K. L. Kees, T. M. Smith, M. L. McCalep, D. H. Prozialeck, R. S. 
Cheeseman, T. E. Christos, W. C. Patt, and K. E. Steiner. Journal of 
Medicinal Chemistry, Vol (35), 944-953, (1992).
 
